Can Medicare International Price Index Model Avoid Part B Demo Pitfalls?
Mandatory nature of demonstration might hamper progress of new model for changing Medicare Part B drug reimbursement, as it did when Obama Administration tried it.
You may also be interested in...
Unique NDCs, Medicare reimbursement codes would allow for lower list prices for the drugs when used in combination for lung cancer, Genentech says.
Muted stakeholder reactions may reflect Trump Administration efforts to address physician concerns in its Medicare Part B drug payment reform.
Medicare spending on Genentech’s Rituxan and Lucentis, and Amgen’s Neulasta and Prolia/Xgeva, would have been $3.8bn less in 2016 using the proposed international pricing index model, CMS estimates.